© Reuters.
By Davit Kirakosyan
Here is your Pro Recap of the biggest analyst picks you may have missed since Friday: upgrades at Dow, Rocket, AstraZeneca, and Coeur Mining.
InvestingPro subscribers got this news first. Never miss another market-moving headline.
Dow raised to Overweight at JPMorgan
Dow (NYSE:) shares rose more than 1% pre-market today after JPMorgan upgraded the company to Overweight from Neutral with a price target of $55.00.
The firm noted that Dow has faced challenges such as weaker demand in China and Europe, domestic capacity increases, replenished inventories, and a sluggish global economy. However, the bank believes “the recent downward movement in equity values has given investors an opportunity to purchase Dow shares at a reasonable valuation”.
According to JPMorgan, the company has a robust balance sheet, offers a 5.6% dividend yield, and the potential for positive responses to higher oil prices.
Rocket upgraded to Hold
CFRA upgraded Rocket (NYSE:) to Hold from Sell with a price target of $8.00, as reported in real-time on InvestingPro. Shares jumped more than 8% pre-market today.
The firm sees Rocket’s fair value closer to its target after a 30% drop from August highs. CFRA maintains its earnings estimates, projecting a loss of $0.15 per share in 2023 and a profit of $0.45 per share in 2024, supported by revenue estimates of $3.97 billion and $5.2B.
Despite challenges in the mortgage market, the firm believes Rocket’s diversified businesses and available liquidity resources position it well.
Two more upgrades
AstraZeneca (NASDAQ:) shares rose more than 1% pre-market today after Jefferies upgraded the company to Buy from Neutral and raised its price target to $80.00 from $66.50.
Last week, the company reported positive high-level results from the TROPION-Breast01 Phase III trial.
RBC Capital upgraded Coeur Mining (NYSE:) to Outperform from Sector Perform with a price target of $4.00. As a result, shares surged more than 7% on Friday.
The expansion at Rochester is almost complete, and execution on the ramp up through mid-2024 is the key catalyst for the stock in our view. The site visit we attended highlighted the +$700m investment in throughput expansion, which should lead to +120% higher production once at full capacity in 2025.
In fast-moving markets, every second counts – and InvestingPro subscribers are always one step ahead with lightning-quick updates.
Start your free 7-day trial now.
Read the full article here